An mRNA vaccine against SARS-CoV-2: Lyophilized, liposome-based vaccine candidate EG-COVID induces high levels of virus neutralizing antibodies
Kim, S.-H.; Cho, Y. J.; Hong, H. C.; Kim, K. S.; Park, S. A.; Chun, M. J.; Hong, E. Y.; Chung, S. W.; Kim, H. J.; Shin, B. G.
Show abstract
In addition to the traditional method of vaccine development, the mRNA coronavirus vaccine, which is attractive as a challenging vaccination, recently opened a new era in vaccinology. Here we describe the EG-COVID which is a novel liposome-based mRNA candidate vaccine that encodes the spike (S) protein of SARS-CoV-2 with 2P-3Q substitution in European variant. We developed the mRNA vaccine platform that can be lyophilized using liposome-based technology. Intramuscular injection of the EG-COVID elicited robust humoral and cellular immune response to SARS-CoV-2. Furthermore, sera obtained from mice successfully inhibited SARS-CoV-2 viral infection into Vero cells. We developed EG-COVID and found it to be effective based on in vitro data, and we plan to initiate a clinical trial soon. Since EG-COVID is a lyophilized mRNA vaccine that is convenient for transportation and storage, accessibility to vaccines will be significantly improved.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Immunogenic Potential of DNA Vaccine candidate, ZyCoV-D against SARS-CoV-2 in Animal Models 93%
- Recombinant SARS-CoV-2 RBD molecule with a T helper epitope as a built in adjuvant induces strong neutralization antibody response 92%
- An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine 92%
Similar papers in this journal
- Optimisation of a Novel Bio-Substrate as a Treatment for Atrophic Age-Related Macular Degeneration. 86%
- Cell-free glycoengineering of the recombinant SARS-CoV-2 spike glycoprotein 85%
- Analysis of genetic signatures of tumor microenvironment yields insight into mechanisms of resistance to immunotherapy 85%
Similar papers in this journal
- A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants 93%
- Evaluation of antibody kinetics and durability in health subjects vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China 91%
- Differential immune response induced by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial 88%
Similar papers in this journal
- A thermally stable protein nanoparticle that stimulates long lasting humoral immune response 91%
- Cell-free screening, production and animal testing of a STI-related chlamydial major outer membrane protein supported in nanolipoproteins. 91%
- Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine 91%
Similar papers in this journal
- Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination 90%
- Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222 90%
- Effectiveness of inactive COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.